[go: up one dir, main page]

MA35636B1 - Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide - Google Patents

Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide

Info

Publication number
MA35636B1
MA35636B1 MA36991A MA36991A MA35636B1 MA 35636 B1 MA35636 B1 MA 35636B1 MA 36991 A MA36991 A MA 36991A MA 36991 A MA36991 A MA 36991A MA 35636 B1 MA35636 B1 MA 35636B1
Authority
MA
Morocco
Prior art keywords
methyl
benzamide
imidazol
pyridinyl
pyrimidinyl
Prior art date
Application number
MA36991A
Other languages
English (en)
Inventor
Upkar Bhardwaj
Mangesh Sadashiv Bordawekar
Ann Reese Comfort
Ping Li
Shoufeng Li
Alexey Makarov
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA35636B1 publication Critical patent/MA35636B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une forme de dosage solide de nilotinib comprenant : (i) un noyau comprenant du 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl-1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide ou un sel pharmaceutiquement acceptable de celui-ci et des excipients; et (ii) au moins un polymère, ledit polymère revêtant ledit noyau, la désintégration de ladite forme de dosage solide étant retardée.
MA36991A 2011-11-14 2014-05-07 Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide MA35636B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14
PCT/US2012/064610 WO2013074432A1 (fr) 2011-11-14 2012-11-12 Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide

Publications (1)

Publication Number Publication Date
MA35636B1 true MA35636B1 (fr) 2014-11-01

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36991A MA35636B1 (fr) 2011-11-14 2014-05-07 Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide

Country Status (22)

Country Link
EP (1) EP2779995A1 (fr)
JP (1) JP6275645B2 (fr)
KR (1) KR20140093230A (fr)
CN (1) CN103930094A (fr)
AR (1) AR088844A1 (fr)
BR (1) BR112014011518A2 (fr)
CA (1) CA2855503A1 (fr)
CL (1) CL2014001247A1 (fr)
CO (1) CO6960546A2 (fr)
EA (1) EA201490960A1 (fr)
GT (1) GT201400094A (fr)
HK (1) HK1197025A1 (fr)
IL (1) IL232480A0 (fr)
IN (1) IN2014DN03416A (fr)
MA (1) MA35636B1 (fr)
MX (1) MX2014005874A (fr)
PE (1) PE20141337A1 (fr)
SG (2) SG11201401476TA (fr)
TN (1) TN2014000177A1 (fr)
TW (1) TWI574690B (fr)
WO (1) WO2013074432A1 (fr)
ZA (1) ZA201402756B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (fr) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide pour utilisation dans le traitement de HCV
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
JP7378279B2 (ja) * 2019-11-18 2023-11-13 日本化薬株式会社 ニロチニブを有効成分とする医薬錠剤及びその製造方法
JP7489849B2 (ja) 2020-07-20 2024-05-24 日本化薬株式会社 ニロチニブ錠剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EP1923053A1 (fr) * 2006-09-27 2008-05-21 Novartis AG Composition pharmaceutique comprenant de la nilotinib ou son sel
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
IN2011CH01887A (fr) * 2011-06-02 2012-12-14

Also Published As

Publication number Publication date
SG11201401476TA (en) 2014-10-30
CO6960546A2 (es) 2014-05-30
HK1197025A1 (en) 2015-01-02
ZA201402756B (en) 2015-04-29
CA2855503A1 (fr) 2013-05-23
CL2014001247A1 (es) 2014-10-17
JP2014533283A (ja) 2014-12-11
NZ623844A (en) 2016-09-30
TWI574690B (zh) 2017-03-21
AU2012339829B2 (en) 2016-05-12
JP6275645B2 (ja) 2018-02-07
MX2014005874A (es) 2014-06-23
TN2014000177A1 (en) 2015-09-30
PE20141337A1 (es) 2014-10-16
EA201490960A1 (ru) 2014-08-29
GT201400094A (es) 2017-09-28
IL232480A0 (en) 2014-06-30
EP2779995A1 (fr) 2014-09-24
IN2014DN03416A (fr) 2015-06-26
SG10201707768RA (en) 2017-10-30
KR20140093230A (ko) 2014-07-25
BR112014011518A2 (pt) 2017-05-16
WO2013074432A1 (fr) 2013-05-23
TW201325594A (zh) 2013-07-01
AR088844A1 (es) 2014-07-10
AU2012339829A1 (en) 2014-05-29
CN103930094A (zh) 2014-07-16

Similar Documents

Publication Publication Date Title
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
CL2012001133A1 (es) Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo.
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
NO20090834L (no) Anvendelse av azabicykloheksanderivater
EP2883875A4 (fr) Dérivé de n2,n4-bis(4-(pipérazine-1-yl)phényl)pirimidine-2,4-diamine ou sel pharmaceutiquement acceptable de celui-ci, et composition contenant celle-ci en tant que substance active pour prévenir ou traiter un cancer
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
RS54608B1 (en) CGRP RECEPTOR ANTAGONITY
MA35716B1 (fr) Formulations pharmaceutiques
MX2021002259A (es) Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato.
MA35636B1 (fr) Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
MX2019001007A (es) Uso novedoso de nectinib y una sal farmaceuticamente aceptable del mismo en el tratamiento contra enfermedades.
HRP20100265T1 (hr) Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti
CR20210043A (es) Forma de dosificación farmacèutica administrable por vía oral con liberación modificada
NZ597864A (en) Methods and compositions for treating leukemia
BRPI0410704A (pt) uso de inibidor c-abl- tirosina quinase, pdgf-r- tirosina quinase, ou c-kit-tirosina quinase no tratamento da diabete
MA35169B1 (fr) Libération modifiée de 4-méthyl-3-[ [4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4- méthyl-1h-imidazol-1-yl)-3-(trifluorométhyl)phényl] benzamide solubilisé à l'aide d'acides organiques
TN2013000440A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
MA50899B1 (fr) Composés utiles pour l'inhibition de cdk7
MX2018009742A (es) "composicion farmaceutica que contiene un derivado de imidazolina".
TH152470A (th) สูตรตำรับ 4-เมธิล-3-[[4-(3-ไพริดินิล-2-ไพริมิดินิลอะมิโน1-n-[5-(4-เมธิล-1h-อิมิดาโซล-1-อิล)-3-(ไตรฟลูออโรเมธิล)ฟีนิล] เบนซาไมด์ชนิดปลดปล่อยทันที
TH155598A (th) ไอโซซาโซลีน (Isoxazolines) ในฐานะเป็นตัวกระทำทางการรักษา ISOXAZOLINES AS THERAPEUTIC AGENTS